NEW YORK, May 7 – Nucleic acid handling company Qiagen said Monday its first quarter revenues rose 26 percent to $63.1 million, compared with $50.2 million in the year ago quarter.

Total operating expenses increased 27 percent to $34.3 million, compared with $27 million in the year ago period, as research and development, sales and marketing, and general and administrative costs rose across the board. Qiagen of Venlo, The Netherlands, also posted expenses totaling $3 million stemming from the acquisition of Japan’s Sawady group of companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.